A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel (R) + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

作者：Sagara Issaka^*; Ellis Ruth D; Dicko Alassane; Niambele Mohamed B; Kamate Beh; Guindo Ousmane; Sissoko Mahamadou S; Fay Michael P; Guindo Merepen A; Kante Ousmane; Saye Renion; Miura Kazutoyo; Long Carole; Mullen Gregory E D; Pierce Mark; Martin Laura B; Rausch Kelly; Dolo Amagana; Diallo Dapa A; Miller Louis H; Doumbo Ogobara K

来源：Vaccine, 2009, 27(52): 7292-7298.

DOI：10.1016/j.vaccine.2009.10.087

• Malaria
• Vaccine
• AMA1-C1
• CPG

A double blind, randomized and controlled Phase 1 clinical trial was conducted to assess the safety and immunogenicity in malaria-exposed adults of the Plasmodium falciparum blood stage vaccine candidate Apical Membrane Antigen 1-Combination 1 (AMA1-C1)/Alhydrogel(R) with and without the novel adjuvant CPG 7909. Participants were healthy adults 18-45 years old living in the village of Donegubougou, Mali. A total of 24 participants received 2 doses one month apart of either 80 mu g AMA1-C1 /Alhydrogel(R) or 80 mu g AMA1-C1/Alhydrogel(R) + 564 mu g CPG 7909. The study started in October 2007 and completed follow up in May 2008. Both vaccines were well tolerated, with only mild local adverse events and no systemic adverse events judged related to vaccination. The difference in antibody responses were over 2-fold higher in the group receiving CPG 7909 for all time points after second vaccination and the differences are statistically significant (all p < 0.05). This is the first use of the novel adjuvant CPG 7909 in a malaria-exposed population.